X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Ophthalmology Product Name: Omidria
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Omeros
Deal Size: $1,326 million Upfront Cash: $126.0 million
Deal Type: Divestment February 06, 2023
Details:
As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Ophthalmology Product Name: Omidria
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Omeros
Deal Size: $1,326 million Upfront Cash: $126.0 million
Deal Type: Divestment December 23, 2021
Details:
As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Ophthalmology Product Name: Omidria
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Omeros
Deal Size: $1,325 million Upfront Cash: $125.0 million
Deal Type: Divestment December 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
